IS8532A - Miðsækin piperidínýl efnasambönd sem kjörvíst bindast integríni - Google Patents
Miðsækin piperidínýl efnasambönd sem kjörvíst bindast integríniInfo
- Publication number
- IS8532A IS8532A IS8532A IS8532A IS8532A IS 8532 A IS8532 A IS 8532A IS 8532 A IS8532 A IS 8532A IS 8532 A IS8532 A IS 8532A IS 8532 A IS8532 A IS 8532A
- Authority
- IS
- Iceland
- Prior art keywords
- integrin
- centrifugal
- selectively bind
- piperidinyl compounds
- piperidinyl
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 125000003386 piperidinyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/782,060 US20040224986A1 (en) | 2002-08-16 | 2004-02-18 | Piperidinyl targeting compounds that selectively bind integrins |
| PCT/US2004/009465 WO2005082889A1 (en) | 2004-02-18 | 2004-03-29 | Piperidinyl targeting compounds that selectively bind integrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8532A true IS8532A (is) | 2006-09-15 |
Family
ID=34911385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8532A IS8532A (is) | 2004-02-18 | 2006-08-17 | Miðsækin piperidínýl efnasambönd sem kjörvíst bindast integríni |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20040224986A1 (is) |
| EP (1) | EP1718635A1 (is) |
| JP (1) | JP2007523907A (is) |
| KR (1) | KR20070010125A (is) |
| CN (1) | CN101023072A (is) |
| AU (1) | AU2004316476A1 (is) |
| BR (1) | BRPI0418552A (is) |
| CA (1) | CA2556768A1 (is) |
| EA (1) | EA200601517A1 (is) |
| EC (1) | ECSP066778A (is) |
| HR (1) | HRP20060298A2 (is) |
| IL (1) | IL177502A0 (is) |
| IS (1) | IS8532A (is) |
| ME (1) | MEP48908A (is) |
| MX (1) | MXPA06009503A (is) |
| NO (1) | NO20064212L (is) |
| RS (1) | RS20060470A (is) |
| WO (1) | WO2005082889A1 (is) |
| ZA (1) | ZA200607756B (is) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
| JP2011519340A (ja) * | 2007-10-30 | 2011-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換アルカン酸調製のためのエナンチオ選択的プロセスこの米国特許正規出願は、2007年10月30日に提出された米国特許仮出願第61/001,004号、及び2008年2月29日に提出された米国特許仮出願第61/067,842号の権利を主張する。 |
| CN102026671B (zh) * | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| US8765743B2 (en) | 2008-06-05 | 2014-07-01 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| WO2010125082A1 (en) | 2009-04-30 | 2010-11-04 | Glaxo Group Limited | Oxazole substituted indazoles as pi3-kinase inhibitors |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| LT3929196T (lt) | 2013-09-24 | 2023-09-25 | Fujifilm Corporation | Farmacinė kompozicija junginio, kurio sudėtyje yra azotas arba jo druska, arba jo metalo kompleksas |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| SI3784269T1 (sl) * | 2018-04-27 | 2024-08-30 | Arrowhead Pharmaceuticals, Inc., | Integrinski ciljni ligandi in njihova uporaba |
| JP2024510196A (ja) * | 2021-03-10 | 2024-03-06 | ダイス・モレキュールズ・エスブイ・インコーポレイテッド | アルファvベータ6およびアルファvベータ1インテグリン阻害剤およびその使用 |
| WO2025067433A1 (zh) * | 2023-09-28 | 2025-04-03 | 云合智药(苏州)生物科技有限公司 | 靶向整合素的化合物及其在RNAi剂中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (is) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| ES2193143T3 (es) * | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
| US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
| EP0822788B1 (en) | 1995-04-19 | 2002-09-04 | Schneider (Usa) Inc. | Drug release coated stent |
| DE19613933A1 (de) | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5919792A (en) * | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
| EP0963370B1 (en) | 1996-12-09 | 2003-03-19 | Eli Lilly And Company | Integrin antagonists |
| PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
| CN1284944A (zh) | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6211191B1 (en) * | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
| EE200000574A (et) | 1998-03-31 | 2002-10-15 | Dupont Pharmaceuticals Company | Farmatseutilised ühendid angiogeensete häirete kuvamiseks |
| UA71586C2 (en) | 1998-12-04 | 2004-12-15 | Smithkline Beecham Corp | A vitronectin receptor antagonist |
| PT1140203E (pt) | 1998-12-18 | 2007-08-30 | Bristol Myers Squibb Pharma Co | Medicamentos antagonistas do receptor da vitronectina |
| EP1140864A2 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| BR9917079A (pt) | 1998-12-18 | 2001-10-30 | Du Pont Pharm Co | Compostos antagonistas de receptor devitronectina, kit, composição metalofarmacêuticade diagnóstico ou terapêutica, composição deagente de contraste para ultra-som, composiçãoradiofarmacêutica terapêutica, composiçãofarmacêutica de diagnóstico, método detratamento da artrite reumatóide, do cancêr e darestenose em um paciente, método de formação deimagem da angiogênese terapêutica, do câncer, denovos vasos sanguìneos, da arteriosclerose, darestenose, da isquemia e da lesão por reperfusãodo miocárdio em um paciente |
| CA2362334A1 (en) | 1999-02-17 | 2000-08-24 | Merck & Co., Inc. | Dibenzo-azepine derivatives as .alpha.v integrin receptor antagonists |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| HUP0302468A2 (hu) | 1999-06-02 | 2003-11-28 | Merck & Co., Inc. | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények |
| ES2244474T3 (es) | 1999-09-29 | 2005-12-16 | Ortho-Mcneil Pharmaceutical, Inc. | Isonipecotamida para el tratamiento de trastornos mediados por integrina. |
| AU2001257526B2 (en) * | 2000-05-04 | 2007-07-19 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US20040009465A1 (en) | 2002-07-12 | 2004-01-15 | Voraphat Luckanatinvong | Shelf life indicator components for fresh cut fruits and vegetables responding to carbondioxide |
| BR0313534A (pt) * | 2002-08-16 | 2005-07-12 | Janssen Pharmaceutica Nv | Antagonistas de integrinade ácido carboxìlico de piperidinoìla |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
-
2004
- 2004-02-18 US US10/782,060 patent/US20040224986A1/en not_active Abandoned
- 2004-03-29 MX MXPA06009503A patent/MXPA06009503A/es unknown
- 2004-03-29 ME MEP-489/08A patent/MEP48908A/xx unknown
- 2004-03-29 RS YUP-2006/0470A patent/RS20060470A/sr unknown
- 2004-03-29 JP JP2006554073A patent/JP2007523907A/ja active Pending
- 2004-03-29 AU AU2004316476A patent/AU2004316476A1/en not_active Abandoned
- 2004-03-29 WO PCT/US2004/009465 patent/WO2005082889A1/en not_active Ceased
- 2004-03-29 CA CA002556768A patent/CA2556768A1/en not_active Abandoned
- 2004-03-29 EP EP04749482A patent/EP1718635A1/en not_active Withdrawn
- 2004-03-29 EA EA200601517A patent/EA200601517A1/ru unknown
- 2004-03-29 KR KR1020067019197A patent/KR20070010125A/ko not_active Withdrawn
- 2004-03-29 HR HR20060298A patent/HRP20060298A2/xx not_active Application Discontinuation
- 2004-03-29 CN CNA2004800427641A patent/CN101023072A/zh active Pending
- 2004-03-29 BR BRPI0418552-8A patent/BRPI0418552A/pt not_active IP Right Cessation
-
2006
- 2006-08-15 IL IL177502A patent/IL177502A0/en unknown
- 2006-08-17 IS IS8532A patent/IS8532A/is unknown
- 2006-08-18 EC EC2006006778A patent/ECSP066778A/es unknown
- 2006-09-15 ZA ZA200607756A patent/ZA200607756B/en unknown
- 2006-09-18 NO NO20064212A patent/NO20064212L/no not_active Application Discontinuation
-
2007
- 2007-08-30 US US11/897,484 patent/US7879881B2/en not_active Expired - Fee Related
-
2010
- 2010-12-22 US US12/975,900 patent/US8110683B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064212L (no) | 2006-11-15 |
| MEP48908A (en) | 2011-02-10 |
| MXPA06009503A (es) | 2007-04-19 |
| AU2004316476A1 (en) | 2005-09-09 |
| US20110092528A1 (en) | 2011-04-21 |
| CN101023072A (zh) | 2007-08-22 |
| US8110683B2 (en) | 2012-02-07 |
| ECSP066778A (es) | 2006-11-16 |
| KR20070010125A (ko) | 2007-01-22 |
| BRPI0418552A (pt) | 2007-05-22 |
| US20040224986A1 (en) | 2004-11-11 |
| WO2005082889A1 (en) | 2005-09-09 |
| EA200601517A1 (ru) | 2007-06-29 |
| ZA200607756B (en) | 2008-06-25 |
| CA2556768A1 (en) | 2005-09-09 |
| US7879881B2 (en) | 2011-02-01 |
| RS20060470A (sr) | 2008-11-28 |
| IL177502A0 (en) | 2006-12-10 |
| US20080058359A1 (en) | 2008-03-06 |
| EP1718635A1 (en) | 2006-11-08 |
| HRP20060298A2 (hr) | 2007-03-31 |
| JP2007523907A (ja) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8532A (is) | Miðsækin piperidínýl efnasambönd sem kjörvíst bindast integríni | |
| DK1874927T3 (da) | Forbedrede cellulaser | |
| ITMI20041252A1 (it) | Composizioni perfluoroelastomeriche | |
| EP1788047A4 (en) | WATER REPELLENT / OIL-REPELLING COMPOSITION | |
| DE602006019282D1 (de) | Schwingungsdämpfende zusammensetzung | |
| DE602006015057D1 (de) | Baumaschine | |
| NO20055686D0 (no) | Sammensetning | |
| DE602005016978D1 (de) | Quecksilberfreisetzende Zusammensetzungen | |
| ATE378256T1 (de) | Verbesserte verpackung | |
| DE102006000112A8 (de) | Separatoreinheit | |
| DE602005017191D1 (de) | Geruchsreduzierte waschstück-zusammensetzung | |
| DE602006007763D1 (de) | Oberfräse | |
| NO20052102D0 (no) | Modem | |
| FR2871686B1 (fr) | Composition anti-decoloration | |
| FI20055346L (fi) | Postiluukku | |
| FI20055202A0 (fi) | Parannettuja sellulaaseja | |
| DK1888099T3 (da) | Hydrerbare keratinsammensætninger | |
| ATE421568T1 (de) | Wäschewaschen | |
| FI20055341L (fi) | Postiluukku | |
| FI20055583A0 (fi) | Vaihtosuuntaajakokoonpano | |
| ITBS20040097A1 (it) | Stendibiancheria | |
| FR2876729B1 (fr) | Passe-paquet | |
| TR200400274U (tr) | Perforeli ambalajlama paketi | |
| ITPD20050117A1 (it) | Macchina diraspatrice | |
| IS8563A (is) | Makrósýklísk efnasambönd sem hindra veirueftirmyndun |